Truist has recently initiated Insmed Inc (INSM) stock to Buy rating, as announced on April 23, 2024, according to Finviz. Earlier, on February 15, 2024, Wolfe Research had initiated the stock to Outperform, setting a price target of $42. Wells Fargo also initiated Overweight rating with a price target of $55. Additionally, JP Morgan resumed Overweight rating on November 20, 2023, with a target price of $36. Guggenheim analysts, in their report published on July 26, 2023, also initiated Buy rating and set a price target of $50 for Insmed Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Insmed Inc (INSM) Stock Trading Recap
On Thursday, Insmed Inc (INSM) stock saw a decline, ending the day at $76.29 which represents a decrease of $-1.71 or -2.19% from the prior close of $78. The stock opened at $78.8 and touched a low of $75.57 during the day, reaching a high of $80.63. The volume of shares traded was 2.41 million exceeding the average volume of 1.79 million.
Sponsored
INSM Stock Performance and Moving Averages
In recent trading, Insmed Inc (INSM) stock price has shown some volatility, fluctuating -1.99% over the last five trades and 9.60% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 4.64%, and it has gained 6.02% in the previous three months. Currently, INSM is trading at 5.44%, 5.50%, and 18.48% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, INSM, a Healthcare sector stock, is trading -5.27% below its 52-week high but remains 248.04% above its 52-week low. The Average True Range (ATR) (14 days) of 2.83 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Insmed Inc’s Profitability and Valuation Ratios
Insmed Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -205.25% and a profit margin of -252.01%, with a gross margin of 4.64%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Insmed Inc’s market capitalization stands at $13.65 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 39.8, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 28.22, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.39% of Insmed Inc (INSM)’s shares, while financial institutions hold 106.04%.
Notable insider trades include Adsett Roger, Chief Operating Officer at Insmed Inc (INSM), who sold 1457 shares on Jan 14 ’25, at $68.72 each, totaling $0.10 million. On Jan 15 ’25, Lewis William, Chair and CEO, sold 31805 shares for $70.18 each, amounting to $2.23 million. Additionally, on Jan 15 ’25, Lewis William sold 6830 shares at $70.17 each, generating $0.48 million.
